Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
P01.02 - Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study
00:00 - 00:00 | Presenter: Hossein Borghaei
- Abstract
Loading...
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P09.18 - COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT)
00:00 - 00:00 | Presenter: Umit Tapan
- Abstract
Loading...
-
+
P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P78.01 - Nivolumab in Second Line Non-Small Cell Lung Cancer – Comparing Real-World Outcomes in England to CheckMate (CM) 017 and 057
00:00 - 00:00 | Presenter: Sanjay Popat
- Abstract
Loading...
-
+
P87 - Targeted Therapy - Clinically Focused - RET
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P87.02 - AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion+ Advanced/Metastatic NSCLC
00:00 - 00:00 | Presenter: Benjamin Besse
- Abstract
Loading...
-
+
ES18 - The Future of Immunotherapy in Unresectable Mesothelioma
- 16:45 - 17:45
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
-
+
ES18.01 - Immunotherapy – Current State of Play (Concentrating on Current Data for First Line and Salvage Strategies)
16:45 - 17:00 | Presenter: Sanjay Popat
- Abstract
Loading...
